Linked Data API

Show Search Form

Search Results

1663756
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Voluntary Scheme for Branded Medicines Pricing and Access more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether he plans to refer the Impact Assessment for the 2023 statutory scheme to control the cost of branded health services medicines to the Regulatory Policy Committee. more like this
tabling member constituency St Albans more like this
tabling member printed
Daisy Cooper more like this
uin 201609 remove filter
answer
answer
is ministerial correction false more like this
date of answer less than 2023-10-20more like thismore than 2023-10-20
answer text <p>There are no plans to refer the statutory scheme Impact Assessment to the Regulatory Policy Committee. The proposals only impact companies which choose to sell to the National Health Service and are therefore considered to be in connection with procurement. Given this, the statutory exclusion from the Better Regulation Framework “Procurement 22(4)(b)” applies as confirmed previously by the Economic and Domestic Affairs Secretariat at Cabinet Office.</p> more like this
answering member constituency Colchester remove filter
answering member printed Will Quince more like this
question first answered
less than 2023-10-20T09:17:48.76Zmore like thismore than 2023-10-20T09:17:48.76Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4769
label Biography information for Daisy Cooper remove filter